Travoprost

Base Information

• Chemical Name: Travoprost
• CAS No.: 157283-68-6
• Deprecated CAS: 207742-69-6
• Molecular Formula: C26H35F3O6
• Molecular Weight: 500.55
• Hs Code.: 2937500000
• European Community (EC) Number: 682-028-9
• UNII: WJ68R08KX9
• ChEMBL ID: CHEMBL1200799
• DSSTox Substance ID: DTXSID80896948
• Metabolomics Workbench ID: 42677
• NCI Thesaurus Code: C47766
• Nikkaji Number: J1.152.432J
• Pharos Ligand ID: HXHZ6RZZBDX4
• RXCUI: 283809
• Wikidata: Q2193376
• Wikipedia: Travoprost
• Mol file: 157283-68-6.mol

Synonyms:(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester;AL 6221;AL-6221;AL6221;Travatan;Travatan Z;travoprost;Z, Travatan

Chemical Property of Travoprost

Chemical Property:

• Appearance/Colour: colorless oil
• Vapor Pressure: 1.61E-14mmHg at 25°C
• Refractive Index: 1.547
• Boiling Point: 584.8 °C at 760 mmHg
• PKA: 13.43±0.20(Predicted)
• Flash Point: 307.5 °C
• PSA: 96.22000
• Density: 1.245 g/cm³
• LogP: 4.42740
• Storage Temp.: −20°C
• Solubility.: Dichloromethane (Sparingly, Sonicated), Chloroform (Sparingy), Methanol (Sparing
• XLogP3: 4.1
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 9
• Rotatable Bond Count: 13
• Exact Mass: 500.23857332
• Heavy Atom Count: 35
• Complexity: 693

Purity/Quality:

99% min ^*data from raw suppliers

Travaprost ^*data from reagent suppliers

Safty Information:

• Pictogram(s): F,Xi
• Hazard Codes: F,Xi
• Statements: 11-36/37/38
• Safety Statements: 16-26-36-7

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O
• Isomeric SMILES: CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)O)O
• Recent ClinicalTrials: Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
• Recent EU Clinical Trials: Additive Effect of Twice Daily Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue
• Recent NIPH Clinical Trials: Switching from latanoprost or travoprost ophthalmolic solution to tafruprost and timolol fixed ophthalmic solution
• Description: Travoprost was launched in the US as Travatan?, an ophthalmic solution (0.004%) administered topically for the treatment of elevated intraocular hypertension (lOP) through open-angle glaucoma, a common optic neuropathy and a leading cause of blindness. Travoprost is the isopropyl ester of (+)-fluprostenol, a new prostaglandin derivative belonging to the PGF2α, analog class. This compound can be prepared in 8 steps from a bicyclic lactone aldehyde by a Wittig alkylidenation followed, after 2 ketonic reductions, by a lactol opening to prostenoic acid while protecting and deprotecting appropriately. Travoprost is a full agonist of FP receptors with a greater affinity than PGF2α, (K1 = 52 nM). Pharmacologic studies in rabbits treated daily for a week demonstrated a significant increase of the microvascular optic nerve head blood flow without significant alterations in the systemic flow. In several placebo-controlled clinical studies with hundreds of patients suffering from open-angle glaucoma or ocular hypertension, travoprost (1 to 4 pm daily) dose-dependently reduced lOP (by about 30% at 4 pm); it was shown equal or superior to latanoprost, another prostaglandin analog (5 pm daily) or the adrenergic ~-blocker timolol (500 pm bid). In addition, travoprost was safe and well tolerated with a low incidence of conjunctival hyperaemia.
• Uses: Travoprost is a selective FP prostaglandin receptor agonist used to treat glaucoma (1,2). treatment conditions arising from excess uric acid, eg chronic gout Selective FP prostaglandin receptor agonist. Isopropyl ester of (+)-fluprostenol. Antiglaucoma